Article Correctness Is Author's Responsibility: Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS

The article below may contain offensive and/or incorrect content.

Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.